Physician profile
Deepa S Patel
NPI 1134225162
$2,854.01
in general payments reported to CMS, 2019-2025
25 companies · $627 in 2025
The $627 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $209 · 2021: $416 · 2022: $353 · 2023: $353 · 2024: $375 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,162.44 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $288.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $192.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $138.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $134.51 | 2024-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.38 | 2022-2025 | |
| Astellas Pharma US INC | $82.57 | 2020-2023 | Veozah |
| Abbvie INC. | $81.60 | 2020-2024 | |
| Pfizer INC. | $74.63 | 2019-2024 | |
| Lilly USA, LLC | $65.57 | 2019 | |
| Amgen INC. | $59.10 | 2022-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $54.31 | 2019-2020 | |
| Abbott Laboratories | $43.80 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $42.41 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $40.63 | 2021-2024 | Rexulti |
| Allergan, INC. | $37.60 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $31.60 | 2021 | |
| Exact Sciences Corporation | $29.89 | 2025 | Cologuard Collection Kit |
| Acadia Pharmaceuticals INC | $28.68 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $26.23 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.50 | 2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $14.21 | 2019 | |
| Daiichi Sankyo INC. | $14.08 | 2022 | |
| Xeris Pharmaceuticals, INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.